Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trialMarta Mosca, Vibeke Strand, Laurent Arnaud et al.|Lupus Science & Medicine|2025Cited by 5
POS0781 EFFICACY AND SAFETY OF ORAL DEUCRAVACITINIB IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS: RESULTS FROM PAISLEY CLE, A GLOBAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIALJ.F. Merola, V.P. Werth, Anna Luisa Kühn et al.|Annals of the Rheumatic Diseases|2025Cited by 5
POS0532 DEUCRAVACITINIB, AN ORAL, ALLOSTERIC, TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT-REPORTED OUTCOMES IN A PHASE 2 TRIALMarta Mosca, Vibeke Strand, Laurent Arnaud et al.|Annals of the Rheumatic Diseases|2024Cited by 0